Anteris Technologies Global Corp. — Capital/Financing Update 2023

Feb 14, 2023

ASX ANNOUNCEMENT

15 February 2023

Settlement of $35 Million Capital Raising Transaction

Anteris Technologies Ltd (ASX: AVR) ( Anteris or the Company ) is pleased to announce the successful settlement of 1.458 million new ordinary shares in the Company to various sophisticated and professional investors at an issue price of $24.00 per New Share, raising $35 million cash. The company’s two largest share-holders Perceptive Advisors and L1 Capital cornerstoned the Placement, each subscribing beyond their existing pro-rata shareholding. The transaction also saw returning investors such as Sio Capital and CEO Wayne Paterson (subject to shareholder approval). Additionally, the Company welcomes New York based Affinity Asset Advisors, a healthcare dedicated fund, into this syndicate.

Participants in the Placement also received one attaching unlisted option to acquire an ordinary share in Anteris for each New Share, expiring two years from the date of issue with an exercise price of $29.00.

In addition, following settlement of the above capital raising, the Company will not be proceeding with its non-binding agreement with Yorkville Advisors Global, LP to provide a $50 million SEPA facility to Anteris, announced on 6 February 2023.

Proceeds from the Placement will be used to further the clinical development of DurAVR™ THV, the Company’s first-in-class, biomimetic TAVR valve technology for the treatment of aortic stenosis, and general working capital purposes.

Anteris also takes this opportunity to announce the milestones in front of the Company in the next 6-12 months. The Company announces that its 15 patient US Early Feasibility Study (EFS) will commence across 7 TAVR Centers of Excellence in early Q2 2023 and will report interim and final 30-day data in Q3 2023. This trial will report 3-month data in Q4 2023, which will proceed to its 12month safety and efficacy milestone for Q2 2024.

In parallel, by late H1 2023 the company will report 12-month data from the second cohort of patients (n=8) from its 13 patient ex-US pilot study. With 12-month ex-US data and 30-day and 3- month data from the US EFS study, Anteris will approach the FDA to finalize the design of their premarket authorization (PMA) trial for US approval of DurAVR[TM] .

This data will build upon the successful 12-month data that was already reported for the first cohort of patients (n=5 of 13) in Jan 2023. Additional clinical milestones will be announced through the course of 2023.

CEO Wayne Paterson commented “With the lineup of clinical work that Anteris will accomplish in 2023 I am very pleased the Company has succeeded in securing multiple routes of capital, through today’s A$35M raise. This kind of capital assurance enables us to march forward confidently with our novel, biomimetic, first-in-class TAVR technology DurAVR[TM] . With our US EFS study initiating in early Q2 2023, the A$35M raise completed today funds the Company through the completion of that trial, release of data and conversations with the FDA towards a plan for the pivotal (PMA) trial for US commercialization.”

Anteris Technologies Ltd Registered Office:

==> picture [95 x 51] intentionally omitted <==

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066 Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris’ DurAVR[TM] 3D single-piece aortic heart valve replacement addresses the needs of today’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.

The proven benefits of its patented ADAPT[®] tissue technology, paired with the unique design of our DurAVR[TM] 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor contact

Deanne Curry GRACosway E: investors@anteristech.com M: +61 414 388 997

Media contact

Nick Howe GRACosway nhowe@gracosway.com.au M: +61 407 183 221

www.anteristech.com Twitter: @AnterisTech Facebook: www.facebook.com/AnterisTech

LinkedIn: https://www.linkedin.com/company/anteristech

==> picture [95 x 52] intentionally omitted <==